DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostic Market - The Future of Diagnostics by Application, Technology and Funding with Executive and Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
Companion Diagnostics is changing the diagnostics industry. Whole new markets are emerging. Diagnostic and Therapeutic partnerships. Find out the latest outlook for this important market.
The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report. The report includes five-year market forecasts.
Will Companion Diagnostics become the norm?
Learn all about how diagnostic players are jockeying for positions with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunities. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost picture is changing.
Companion Diagnostic Markets report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand New Nucleic Acid Testing pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions.
Specific growth and market size estimates for your area of interest is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges
Key Topics Covered:
1 Market Guides
1.1 Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 What are Companion Diagnostics?
2.2 The Personalized Medicine Revolution
2.3 Market Definition
2.4 Methodology
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
3 Market Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Instrumentation Supplier
3.1.4 Chemical/Reagent Supplier
3.1.5 Pathology Supplier
3.1.6 Independent Clinical Laboratory
3.1.7 Public National/regional Laboratory
3.1.8 Hospital Laboratory
3.1.9 Physicians Office Lab (POLS)
3.1.10 Audit Body
3.1.11 Certification Body
3.2 Personalized Medicine and Companion Diagnostics
3.2.1 Basics
3.2.2 Method
3.2.3 Disease risk assessment
3.2.4 Applications
3.2.5 Diagnosis and Intervention
3.2.5.1 Companion Diagnostics
3.2.6 Drug development and usage
3.2.7 Respiratory proteomics
3.2.8 Cancer genomics
3.2.9 Population screening
3.2.10 Challenges
3.2.11 Regulatory oversight
3.2.12 Intellectual property rights
3.2.13 Reimbursement policies
3.2.14 Patient privacy and confidentiality
3.3 Chromosomes, Genes and Epigenetics
3.3.1 Chromosomes
3.3.2 Genes
3.3.3 Epigenetics
3.4 Cancer Genes
3.4.1 Germline vs Somatic
3.4.2 Changing Clinical Role
3.5 Structure of Industry Plays a Part
3.5.1 New Pharmaceutical Funding Market
3.5.2 Economies of Scale
3.5.2.1 Hospital vs. Central Lab
3.5.3 Physician Office Labs
3.5.4 Physicians and POCT
4 Market Trends
4.1 Factors Driving Growth
4.1.1 Level of Care.
4.1.2 Immuno-oncology.
4.1.3 Liability.
4.1.4 The Aging World
4.2 Factors Limiting Growth
4.2.1 State of knowledge.
4.2.2 Genetic Blizzard.
4.2.3 Protocol Resistance.
4.2.4 Regulation and coverage.
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.5 PCR Takes Command
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
5 Companion Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Foundation Medicine, Repare to Partner on CDx for Lunresertib
5.3 Burning Rock, Bayer to Develop NGS Companion Diagnostic
5.4 PathAI, Roche to Develop AI-Enabled Companion Diagnostics
5.5 ARUP and Medicover Expand Companion Diagnostic in EU
5.6 Thermo Fisher Signs Companion Diagnostic Agreement
5.7 Agilent CDx Assay IVDR Certified
5.8 ARUP Laboratories Gets Approval for Gene Therapy CDx
5.9 Guardant Health Gets Medicare Coverage for Liquid Biopsy Test
5.10 Amoy Dx PLC Panel Gets Approval in Japan as CDx
5.11 UnitedHealthcare Expands Precision Oncology Dx Coverage
5.12 JaxBio to Create Array-Based Cancer Tests
5.13 Agilent, Qiagen Win FDA Approvals Companion Diagnostics
5.14 Navignostics Using Single-Cell Spatial Proteomics
5.15 HMNC Brain Health to Develop Companion Diagnostics
5.16 Propath UK, Nucleai Partner on Spatial Proteomics
5.17 Becton Dickinson, Labcorp Develop Flow Cytometry Companion Diagnostics
5.18 Almac, AstraZeneca Strike CDx Development Pact
5.19 Avalon GloboCare to Develop Cell Therapy CDx
5.20 Burning Rock Secures Lung Cancer NGS Test Approval in China
5.21 TenSixteen Bio Developing Drugs, Companion NGS Tests
5.22 Guardant Health Plans New Comprehensive Assay
5.23 Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs
5.24 Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test
5.25 Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx
5.26 Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug
5.27 Natera Aims to Lead Market in Solid Tumor Adjuvant CDx
5.28 Oncocyte Details Expansions Plans
5.29 Agilent Acquires Resolution Biosciences
5.30 Qiagen, Inovio Expand CDx Partnership
5.31 AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
5.32 NeoGenomics to Grow Through CDx Agreements, Acquisitions
5.33 Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
5.34 Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
5.35 FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
5.36 Promega to Develop MSI Assay as CDx
5.37 Guardant Health to Develop CDx for Janssen
5.38 Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
5.39 FDA Approval for FoundationOneCDx
5.40 FDA finalizes CDx Guidance
5.41 QIAGEN Launches CDx Therascreen BRAF Test
6 Profiles of Key Players
6.1 10x Genomics, Inc.
6.2 Abbott Laboratories
6.3 AccuraGen Inc.
6.4 Acuamark Diagnostics
6.5 Adaptive Biotechnologies
6.6 Admera Health, LLC
6.7 Aethlon Medical
6.8 Agilent
6.9 Amoy Diagnostics Co., Ltd.
6.10 Anchor Dx
6.11 ANGLE plc
6.12 Applied DNA Sciences
6.13 ARUP Laboratories
6.14 AVIVA Systems Biology
6.15 Baylor Miraca Genetics Laboratories
6.16 Beckman Coulter Diagnostics (Danaher)
6.17 Becton, Dickinson and Company
6.18 Berkley Lights
6.19 BGI Genomics Co. Ltd
6.20 BillionToOne
6.21 Bioarray Genetics
6.22 Biocartis
6.23 Biocept, Inc.
6.24 Biodesix Inc.
6.25 BioFluidica
6.26 BioGenex
6.27 BioIVT
6.28 Biolidics Ltd
6.29 bioMerieux Diagnostics
6.30 Bioneer Corporation
6.31 Bio-Rad Laboratories, Inc
6.32 Bio-Reference Laboratories
6.33 Bio-Techne
6.34 Bioview
6.35 Bristol-Myers Squibb
6.36 Burning Rock
6.37 C2i Genomics
6.38 Cardiff Oncology
6.39 Caris Molecular Diagnostics
6.40 Castle Biosciences, Inc.
6.41 CellCarta
6.42 CellMax Life
6.43 Cepheid (Danaher)
6.44 Charles River Laboratories
6.45 Circulogene
6.46 Cizzle Biotech
6.47 Clearbridge Biomedics
6.48 Clinical Genomics
6.49 Cytolumina Technologies Corp.
6.50 Datar Cancer Genetics Limited
6.51 Diagnologix LLC
6.52 Diasorin S.p.A.
6.53 Dxcover
6.54 Element Biosciences
6.55 Enzo Biochem
6.56 Epic Sciences
6.57 Epigenomics AG
6.58 Eurofins Scientific
6.59 Fabric Genomics
6.60 Fluxion Biosciences (Cell Microsystems)
6.61 Freenome
6.62 FUJIFILM Wako Diagnostics
6.63 Fujirebio
6.64 Fyr Diagnostics
6.65 GeneDx Holdings
6.66 GeneFirst Ltd.
6.67 Genetron Holdings
6.68 GenomOncology
6.69 GILUPI Nanomedizin
6.70 Guardant Health
6.71 HansaBiomed
6.72 HTG Molecular Diagnostics
6.73 iCellate
6.74 ICON PLC
6.75 Illumina
6.76 Incell Dx
6.77 Inivata
6.78 INOVIQ
6.79 Invitae Corporation
6.80 Invivogen
6.81 Invivoscribe
6.82 J&J Innovative Medicine
6.83 KEW
6.84 Lucence Health
6.85 Lunglife AI Inc
6.86 MDNA Life SCIENCES, Inc.
6.87 MDx Health
6.88 Menarini Silicon Biosystems
6.89 Mesa Laboratories, Inc.
6.90 Millipore Sigma
6.91 Miltenyi Biotec
6.92 miR Scientific
6.93 Myriad Genetics
6.94 Nanostring
6.95 NantHealth, Inc.
6.96 Natera
6.97 NeoGenomics
6.98 NGeneBio
6.99 Novogene
6.100 Oncimmune
6.101 Oncocyte
6.102 OncoDNA
6.103 Oncohost
6.104 Oxford Nanopore Technologies
6.105 PamGene
6.106 Panagene
6.107 Personalis
6.108 Perthera
6.109 PGDx (Labcorp)
6.110 Precipio
6.111 PrecisionMed
6.112 Predicine
6.113 Predictive Oncology
6.114 Prenetics
6.115 Promega
6.116 Qiagen
6.117 QuidelOrtho
6.118 Rarecells SAS
6.119 RareCyte
6.120 Revvity
6.121 Roche Diagnostics
6.122 Screencell
6.123 Sherlock Biosciences
6.124 Siemens Healthineers
6.125 Singlera Genomics Inc.
6.126 Singular Genomics
6.127 Singulomics
6.128 SkylineDx
6.129 Standard BioTools
6.130 Stilla Technologies
6.131 Sysmex Inostics
6.132 Tempus Labs, Inc.
6.133 Thermo Fisher Scientific
6.134 Todos Medical
6.135 Ultima Genomics
6.136 Veracyte
6.137 Vir
6.138 VolitionRX
6.139 Vortex Biosciences
7 The Global Market for Companion Diagnostics
7.1 Global Market Overview by Country
7.2 Global Market by Application - Overview
7.3 Global Market Funding Source - Overview
7.4 Global Market Technology - Overview
8 Global Companion Diagnostic Markets - By Application
8.1 Oncology Breast
8.2 Oncology Lungry
8.3 Oncology Colorectal
8.4 Oncology Other
8.5 Neurology
8.6 Cardiology
8.7 Other Application
9 Global Companion Diagnostic Markets - Funding Source
9.1 Global Market Pharmaceutical
9.2 Global Market Venture
9.3 Global Market Clinical
9.4 Global Market Other Funding
10 Global Companion Diagnostic Markets - Technology
10.1 Global Market Next Generation Sequencing
10.2 Global Market PCR
10.3 Global Market IHC/ISH
10.4 Global Market Other Technology
11 Appendices
11.1 United States Medicare System: Clinical Laboratory Fees Schedule
11.2 The Most Used IVD Assays
11.3 The Highest Grossing Assays
For more information about this report visit https://www.researchandmarkets.com/r/tlb3ww
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
